Glychek-M Plus Tablet contains a combination of Gliclazide 40mg and Metformin 500mg, formulated for the effective management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glycemic control. This dual-action mechanism addresses hyperglycemia through complementary pathways, making Glychek-M Plus suitable for patients inadequately controlled by diet and exercise alone or those requiring combination therapy. The tablet is indicated for adults with type 2 diabetes to improve glycemic parameters and reduce the risk of diabetes-related complications. It is essential to use Glychek-M Plus alongside lifestyle modifications, including diet and physical activity, for optimal therapeutic outcomes. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose and renal function is recommended. Common side effects may include gastrointestinal disturbances and hypoglycemia; therefore, patient education on symptom recognition and management is crucial. Glychek-M Plus should be prescribed and used under medical supervision to ensure safety and efficacy in diabetes management.